In-vivo treatment accuracy analysis of active motion-compensated liver SBRT through registration of plan dose to post-therapeutic MRI-morphologic alterations.

CONCLUSIONS: For the first time a method for IVA was presented, which can serve as a benchmarking-tool for other treatment techniques. Both techniques have shown median deviations <5 mm of planned dose and MMA. However, IVA also revealed treatments with errors ≥5 mm, suggesting a necessity for patient-specific safety-margins. Nevertheless, the treatment accuracy of well-performed active motion-compensated liver SBRT seems not to be a driving factor for local treatment failure. PMID: 31005210 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31005210?dopt=Abstract

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 23, 2019 Category: Radiology Authors: Boda-Heggemann J, Jahnke A, Chan MKH, Ernst F, Ghaderi AL, Attenberger U, Hunold P, Schäfer JP, Wurster S, Rades D, Hildebrandt G, Lohr F, Dunst J, Wenz F, Blanck O Tags: Radiother Oncol Source Type: research